Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial - Summary - MDSpire

Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial

  • By

  • Jiali Li

  • Sha Zhou

  • Xiaoping Li

  • Xiangyu Ma

  • Sanbin Wang

  • Yicheng Zhang

  • Shifeng Lou

  • Jun Rao

  • Ping Wang

  • Lidan Zhu

  • Ting Chen

  • Xixi Xiang

  • Shichun Gao

  • Han Yao

  • Peiyan Kong

  • Lei Gao

  • Cheng Zhang

  • Xi Zhang

  • Li Gao

  • June 24, 2026

  • 0 min

Share

Objective:

To compare the efficacy and safety of single-dose Pegylated G-CSF (Peg-G-CSF) versus daily G-CSF in mobilizing peripheral blood stem cells (PBSC) in healthy donors.

Approach:
  • Method: A
  • Method: m
  • Method: u
  • Method: l
  • Method: t
  • Method: i
  • Method: c
  • Method: e
  • Method: n
  • Method: t
  • Method: e
  • Method: r
  • Method: ,
  • Method: r
  • Method: a
  • Method: n
  • Method: d
  • Method: o
  • Method: m
  • Method: i
  • Method: z
  • Method: e
  • Method: d
  • Method: c
  • Method: o
  • Method: n
  • Method: t
  • Method: r
  • Method: o
  • Method: l
  • Method: l
  • Method: e
  • Method: d
  • Method: t
  • Method: r
  • Method: i
  • Method: a
  • Method: l
  • Method: c
  • Method: o
  • Method: n
  • Method: d
  • Method: u
  • Method: c
  • Method: t
  • Method: e
  • Method: d
  • Method: f
  • Method: r
  • Method: o
  • Method: m
  • Method: M
  • Method: a
  • Method: y
  • Method: 2
  • Method: 0
  • Method: 1
  • Method: 8
  • Method: t
  • Method: o
  • Method: A
  • Method: p
  • Method: r
  • Method: i
  • Method: l
  • Method: 2
  • Method: 0
  • Method: 1
  • Method: 9
  • Method: w
  • Method: i
  • Method: t
  • Method: h
  • Method: h
  • Method: e
  • Method: a
  • Method: l
  • Method: t
  • Method: h
  • Method: y
  • Method: d
  • Method: o
  • Method: n
  • Method: o
  • Method: r
  • Method: s
  • Method: r
  • Method: e
  • Method: c
  • Method: e
  • Method: i
  • Method: v
  • Method: i
  • Method: n
  • Method: g
  • Method: e
  • Method: i
  • Method: t
  • Method: h
  • Method: e
  • Method: r
  • Method: 1
  • Method: 2
  • Method: m
  • Method: g
  • Method: P
  • Method: e
  • Method: g
  • Method: -
  • Method: G
  • Method: -
  • Method: C
  • Method: S
  • Method: F
  • Method: o
  • Method: r
  • Method: 1
  • Method: 0
  • Method: µ
  • Method: g
  • Method: /
  • Method: k
  • Method: g
  • Method: /
  • Method: d
  • Method: G
  • Method: -
  • Method: C
  • Method: S
  • Method: F
  • Method: .
Key Findings:
  • 83.3% of donors in the Peg-G-CSF group and 79.2% in the G-CSF group collected ≥4×10^6 CD34+ cells/kg.
  • Median yield of CD34+ cells was comparable between both groups.
  • No significant differences in side effects were observed, and there were no significant differences in engraftment, graft-versus-host disease (GVHD), or survival between groups.
Interpretation:

Single injection of Peg-G-CSF is as effective and safe as traditional daily G-CSF for PBSC mobilization.

Limitations:
  • The study was limited to a specific population of healthy donors related to acute leukemia recipients.
  • Follow-up loss of donors was considered in sample size estimation.
Conclusion:

Peg-G-CSF offers a viable alternative to daily G-CSF for PBSC mobilization, maintaining efficacy and safety.

Sources:

Original Source(s)

Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial

  • by Jiali Li, Sha Zhou, Xiaoping Li, Xiangyu Ma, Sanbin Wang, Yicheng Zhang, Shifeng Lou, Jun Rao, Ping Wang, Lidan Zhu, Ting Chen, Xixi Xiang, Shichun Gao, Han Yao, Peiyan Kong, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao

  • June 24, 2026

Related Content

Editorial: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

Which Patients Seek Second Opinions?

A Keck Medicine of USC hematologist-oncologist shares his insights on second opinions.

  • February 26, 2025

  • 6 min
Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China